left ventricular ejection fraction
Item
have a left ventricular ejection fraction (lvef) 40 percent, as assessed by any method, e.g., echocardiography, a multigated acquisition (muga) scan or magnetic resonance imaging (mri);
boolean
C0428772 (UMLS CUI [1])
hospitalization with signs and symptoms of ahf
Item
present with signs and symptoms considered to be primarily due to ahf and be admitted to the hospital for ahf;
boolean
C0264714 (UMLS CUI [1])
C0019993 (UMLS CUI [2])
Patient is ambulatory prior to admission
Item
confirmation verbally that the patient was ambulatory, i.e., able to walk >30m, prior to developing symptoms of ahf leading to the current admission;
boolean
C3693818 (UMLS CUI [1])
Informed consent
Item
be capable of understanding the nature of the trial; be willing and able to comply with the inpatient and outpatient study protocol requirements for the duration of the study; and be willing to participate, as documented by written informed consent.
boolean
C0021430 (UMLS CUI [1])
systolic blood pressure
Item
have a systolic blood pressure <90mmhg or >170mmhg at baseline;
boolean
C0871470 (UMLS CUI [1])
have an anticipated need for an invasive procedure within 3 days of study enrollment
Item
have an anticipated need for an invasive procedure within 3 days of study enrollment, e.g., due to hemodynamic or cardiac rhythm instability, or acute coronary syndrome, requiring procedures including, but not limited to, cardiac catheterization, placement of a defibrillator/pacemaker, or placement of a pulmonary artery catheter;
boolean
C1548804 (UMLS CUI [1])
have a primary hf etiology attributable to either restrictive/obstructive cardiomyopathy, idiopathic hypertrophic cardiomyopathy that is obstructive, or uncorrected severe valvular disease
Item
have a primary hf etiology attributable to either restrictive/obstructive cardiomyopathy, idiopathic hypertrophic cardiomyopathy (as defined by any wall thickness > 1.8cm) that is obstructive, or uncorrected severe valvular disease (except mitral regurgitation);
boolean
C0018801 (UMLS CUI [1])
C0878544 (UMLS CUI [2])
C3258293 (UMLS CUI [3])
have any other comorbidities that limit ambulation more than the patient's heart failure
Item
have any other comorbidities that limit ambulation more than the patient's heart failure, e.g., symptomatic peripheral arterial disease, copd, arthritis or other condition, as confirmed verbally with the patient;
boolean
C0525058 (UMLS CUI [1])
C0439801 (UMLS CUI [2])
C0009488 (UMLS CUI [3])
have severe renal insufficiency
Item
have severe renal insufficiency (defined as a gfr <30ml/min/1.73m2 according to the mdrd equation);
boolean
C0035078 (UMLS CUI [1])
have an anticipated survival of less than 90 days
Item
have an anticipated survival of less than 90 days, for any reason;
boolean
C0023671 (UMLS CUI [1])
study subject participation status
Item
have received an investigational agent (drug, device or biologic product) within 30 days (or, if longer, 5 half-lives for a drug or biologic agent) prior to study entry, or be planning to receive an investigational agent at any time throughout the full duration of the study until at least study day 35;
boolean
C2348568 (UMLS CUI [1])
have any other clinically significant laboratory abnormality, medical condition or social circumstance that, in the investigator's opinion, makes it inappropriate for the patient to participate in this clinical trial.
Item
have any other clinically significant laboratory abnormality, medical condition or social circumstance that, in the investigators opinion, makes it inappropriate for the patient to participate in this clinical trial.
boolean
C0525058 (UMLS CUI [1])
C0439801 (UMLS CUI [2])
C0009488 (UMLS CUI [3])